Clinica's New Stock Tracker - featured stock: Genoptix
This article was originally published in Clinica
Stock Highlight: Genoptix (GXDX) +105% The current turbulent global financial markets have sent medtech shares yo-yoing during the first few months of 2008. Financial uncertainty has resulted in the postponement of many IPOs, including that of French ophthalmic equipment specialist Luneau Technology, which cancelled its IPO on the Euronext's Alternext market on January 29.
You may also be interested in...
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.
With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.